准分子激光手术矫正散光性屈光不正的长期疗效。
Long-term results of excimer laser procedure to correct astigmatic refractive errors.
机构信息
Ophthalmology Unit, Department of Surgical Specialties, University Hospital of Messina, Messina, Italy.
出版信息
Med Sci Monit. 2013 Nov 4;19:927-33. doi: 10.12659/MSM.884023.
BACKGROUND
The aim of this study was to evaluate long-term efficacy, safety, stability, and predictability of photorefractive keratectomy (PRK) as treatment of astigmatism.
MATERIAL/METHODS: Ninety-four eyes of 52 patients, treated with PRK for compound myopic astigmatism, compound hyperopic astigmatism, and mixed astigmatism were studied during a 36-month period. Main outcome measures were uncorrected and best-corrected visual acuity (UCVA, BCVA), refraction, and corneal transparency. Astigmatism correction was analyzed by a power vector method.
RESULTS
In myopic astigmatism group (42 eyes), postoperative UCVA was 20/40 or better in 100% of eyes, 20/25 or better in 38 eyes out of 42 (90.5%), and 20/20 or better in 25/42 eyes (59.5%). No eye lost lines of the BCVA, 40/42 (95.2%) eyes had refraction within ± 1D and 37/42 (88.1%) within ± 0.50 D. In the hyperopic astigmatism group (28 eyes), the UCVA was 20/40 or better in 100% of eyes, 20/25 or better in 26/28 eyes (92.8%), and 20/20 or better in 24/28 eyes (85.7%); 1/28 eyes (3.6%) lost 1 line of the BCVA, 23/28 eyes (82.1%) were within ± 1D, and 21/28 (75%) were within ± 0.50D. In the mixed astigmatism group (24 eyes), the UCVA was 20/40 or better in 100% of eyes, 20/25 or better in 22/24 eyes (91.7%) and 20/20 in 15/24 (62.5%) eyes. No eye lost lines of BCVA, 23/24 eyes (95.8%) were within 1.0 D, and 20/24 eyes (83.3%) were within 0.50 D of defocus refraction. Power vector analysis showed a significant reduction of blurring strength in all examined groups.
CONCLUSIONS
PRK is a safe and effective procedure for correction of all types of astigmatism, with good stability and efficacy at 3-year follow-up.
背景
本研究旨在评估准分子激光角膜切削术（PRK）治疗散光的长期疗效、安全性、稳定性和可预测性。
材料/方法：52 例（94 只眼）患者接受 PRK 治疗复性近视散光、复性远视散光和混合散光，随访 36 个月。主要观察指标为未矫正视力（UCVA）、最佳矫正视力（BCVA）、屈光度和角膜透明度。散光矫正采用屈光矢量分析法。
结果
近视性散光组（42 只眼）术后 UCVA 为 20/40 或更佳者占 100%，20/25 或更佳者占 38 只眼（90.5%），20/20 或更佳者占 25 只眼（59.5%）。无一例 BCVA 下降 1 行，42 只眼中 40 只眼（95.2%）屈光度在±1.0D 以内，37 只眼（88.1%）在±0.50D 以内。远视性散光组（28 只眼）术后 UCVA 为 20/40 或更佳者占 100%，20/25 或更佳者占 26 只眼（92.8%），20/20 或更佳者占 24 只眼（85.7%）；1 只眼（3.6%）BCVA 下降 1 行，28 只眼中 23 只眼（82.1%）屈光度在±1.0D 以内，21 只眼（75%）在±0.50D 以内。混合性散光组（24 只眼）术后 UCVA 为 20/40 或更佳者占 100%，20/25 或更佳者占 22 只眼（91.7%），20/20 或更佳者占 15 只眼（62.5%）。无一例 BCVA 下降 1 行，24 只眼中 23 只眼（95.8%）屈光度在±1.0D 以内，20 只眼（83.3%）在±0.50D 以内。屈光矢量分析显示各组散光度均显著降低。
结论
PRK 是一种安全有效的治疗各种类型散光的方法，3 年随访时疗效稳定。
Zotero 插件